165 related articles for article (PubMed ID: 1993909)
1. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Brem H; Mahaley MS; Vick NA; Black KL; Schold SC; Burger PC; Friedman AH; Ciric IS; Eller TW; Cozzens JW
J Neurosurg; 1991 Mar; 74(3):441-6. PubMed ID: 1993909
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Brem H; Piantadosi S; Burger PC; Walker M; Selker R; Vick NA; Black K; Sisti M; Brem S; Mohr G
Lancet; 1995 Apr; 345(8956):1008-12. PubMed ID: 7723496
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
[TBL] [Abstract][Full Text] [Related]
4. Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol.
Ramos-Fresnedo A; Al-Kharboosh R; Twohy EL; Basil AN; Szymkiewicz EC; Zubair AC; Trifiletti DM; Durand N; Dickson DW; Middlebrooks EH; Abarbanel DN; Tzeng SY; Almeida JP; Chaichana KL; Green JJ; Sherman WJ; Quiñones-Hinojosa A
Neurosurg Pract; 2023 Dec; 4(4):. PubMed ID: 38464470
[TBL] [Abstract][Full Text] [Related]
5. Targeted Glioma Therapy-Clinical Trials and Future Directions.
Shikalov A; Koman I; Kogan NM
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258110
[TBL] [Abstract][Full Text] [Related]
6. Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Champeaux-Depond C; Jecko V; Weller J; Constantinou P; Tuppin P; Metellus P
J Neurooncol; 2023 Apr; 162(2):343-352. PubMed ID: 36991304
[TBL] [Abstract][Full Text] [Related]
7. Injectable pH Thermo-Responsive Hydrogel Scaffold for Tumoricidal Neural Stem Cell Therapy for Glioblastoma Multiforme.
King JL; Maturavongsadit P; Hingtgen SD; Benhabbour SR
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297678
[TBL] [Abstract][Full Text] [Related]
8. A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults.
Ekhator C; Rak R; Tadipatri R; Fonkem E; Grewal J
Cureus; 2022 Aug; 14(8):e28175. PubMed ID: 36148206
[TBL] [Abstract][Full Text] [Related]
9. Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release.
Hauck M; Dittmann J; Zeller-Plumhoff B; Madurawala R; Hellmold D; Kubelt C; Synowitz M; Held-Feindt J; Adelung R; Wulfinghoff S; Schütt F
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456611
[TBL] [Abstract][Full Text] [Related]
10. Well-Defined Polyethylene Glycol Microscale Hydrogel Blocks Containing Gold Nanorods for Dual Photothermal and Chemotherapeutic Therapy.
Newland B; Starke J; Bastiancich C; Gonçalves DPN; Bray LJ; Wang W; Werner C
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335927
[TBL] [Abstract][Full Text] [Related]
11. Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
Gazaille C; Sicot M; Saulnier P; Eyer J; Bastiat G
Front Med Technol; 2021; 3():791596. PubMed ID: 35047971
[TBL] [Abstract][Full Text] [Related]
12. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
[TBL] [Abstract][Full Text] [Related]
13. Injectable biomaterials for treatment of glioblastoma.
Anderson AR; Segura T
Adv Mater Interfaces; 2020 Oct; 7(20):. PubMed ID: 34660174
[TBL] [Abstract][Full Text] [Related]
14. Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Nishikawa R; Iwata H; Sakata Y; Muramoto K; Matsuoka T
Neurol Med Chir (Tokyo); 2021 Sep; 61(9):536-548. PubMed ID: 34092748
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.
Keutgen XM; Ornell KJ; Vogle A; Lakiza O; Williams J; Miller P; Mistretta KS; Setia N; Weichselbaum RR; Coburn JM
Ann Surg Oncol; 2021 Dec; 28(13):8532-8543. PubMed ID: 34091777
[TBL] [Abstract][Full Text] [Related]
16. Neurosurgical involvement in clinical trials for CNS tumors.
Vogelbaum MA; Parney IF; Elder JB; Cahill D
J Neurooncol; 2021 Feb; 151(3):367-373. PubMed ID: 33611704
[TBL] [Abstract][Full Text] [Related]
17. Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.
Griffith JI; Rathi S; Zhang W; Zhang W; Drewes LR; Sarkaria JN; Elmquist WF
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33322488
[TBL] [Abstract][Full Text] [Related]
18. Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis.
Xiao ZZ; Wang ZF; Lan T; Huang WH; Zhao YH; Ma C; Li ZQ
Front Neurol; 2020; 11():1036. PubMed ID: 33041980
[No Abstract] [Full Text] [Related]
19. Focused Ultrasound for Noninvasive, Focal Pharmacologic Neurointervention.
Wang JB; Di Ianni T; Vyas DB; Huang Z; Park S; Hosseini-Nassab N; Aryal M; Airan RD
Front Neurosci; 2020; 14():675. PubMed ID: 32760238
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
